Published in Hepatology on April 01, 2004
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature (2012) 1.82
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
The bile salt export pump. Pflugers Arch (2006) 1.34
Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. Gastroenterology (2006) 1.29
Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins. Proc Natl Acad Sci U S A (2013) 1.05
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Rho kinase, myosin-II, and p42/44 MAPK control extracellular matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells. Mol Biol Cell (2006) 1.00
Cytokinesis defines a spatial landmark for hepatocyte polarization and apical lumen formation. J Cell Sci (2014) 0.91
Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem Cell Biol (2007) 0.89
Animal models for the study of HCV. Curr Opin Virol (2015) 0.86
Morphogenetic competence of HNF4 alpha-deficient mouse hepatic cells. J Hepatol (2008) 0.83
Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. J Virol (2015) 0.80
Loss of a Candidate Biliary Atresia Susceptibility Gene, add3a, Causes Biliary Developmental Defects in Zebrafish. J Pediatr Gastroenterol Nutr (2016) 0.77
Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. Scientifica (Cairo) (2012) 0.77
Hepatocytes traffic and export hepatitis B virus basolaterally by polarity-dependent mechanisms. J Virol (2011) 0.77
Novel regulation of Ski protein stability and endosomal sorting by actin cytoskeleton dynamics in hepatocytes. J Biol Chem (2015) 0.75
Diabetes consequences in the fetus liver of the non-obese diabetic mice. Nutr Diabetes (2017) 0.75
PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis. World J Hepatol (2017) 0.75
Concise Review: Advances in Generating Hepatocytes from Pluripotent Stem Cells for Translational Medicine. Stem Cells (2016) 0.75
Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev (2003) 3.07
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol Sci (2006) 2.00
OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology (2005) 1.69
Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology (2006) 1.54
The Comparative Toxicogenomics Database (CTD). Environ Health Perspect (2003) 1.48
Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion. Hepatology (2013) 1.46
Drug-induced cholestasis. Hepatology (2011) 1.39
Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem (2003) 1.35
Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem (2003) 1.34
Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. Gastroenterology (2006) 1.29
Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology (2010) 1.26
Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology (2010) 1.21
ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology (2008) 1.21
Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol (2004) 1.12
Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. J Lipid Res (2010) 1.08
Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II. Hepatology (2008) 1.07
The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J Clin Invest (2002) 1.06
Liver biopsy: evolving role in the new millennium. J Clin Gastroenterol (2005) 1.06
Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J Biol Chem (2003) 1.05
OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Front Biosci (Landmark Ed) (2009) 1.05
The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol (2007) 1.03
Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol (2010) 1.02
Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. Gastroenterology (2002) 1.02
Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol Cell Physiol (2007) 1.02
Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. Hepatology (2009) 1.02
Oxidative stress and hepatic stellate cell activation are key events in arsenic induced liver fibrosis in mice. Toxicol Appl Pharmacol (2010) 0.99
NHERF-1 binds to Mrp2 and regulates hepatic Mrp2 expression and function. J Biol Chem (2010) 0.98
An evolutionarily ancient Oatp: insights into conserved functional domains of these proteins. Am J Physiol Gastrointest Liver Physiol (2002) 0.96
The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis (2010) 0.95
The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology (2013) 0.95
Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A (2014) 0.94
Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis (2010) 0.93
Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine. Am J Physiol Gastrointest Liver Physiol (2012) 0.91
Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2). J Lipid Res (2012) 0.91
FXR: a target for cholestatic syndromes? Expert Opin Ther Targets (2006) 0.90
Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int (2005) 0.90
Molecular characterization of a multidrug resistance-associated protein, Mrp2, from the little skate. Am J Physiol Regul Integr Comp Physiol (2002) 0.89
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology (2004) 0.89
Arsenic (+ 3 oxidation state) methyltransferase and the methylation of arsenicals in the invertebrate chordate Ciona intestinalis. Toxicol Sci (2009) 0.88
Ostα depletion protects liver from oral bile acid load. Am J Physiol Gastrointest Liver Physiol (2011) 0.88
Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology (2002) 0.88
Role of breast cancer resistance protein in the adaptive response to cholestasis. Drug Metab Dispos (2010) 0.87
Cholestatic syndromes. Curr Opin Gastroenterol (2004) 0.86
Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis (2002) 0.86
Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.85
Down-regulation of the Na+/taurocholate cotransporting polypeptide during pregnancy in the rat. J Hepatol (2003) 0.85
N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta. BMC Cell Biol (2008) 0.85
Exploiting genome data to understand the function, regulation, and evolutionary origins of toxicologically relevant genes. EHP Toxicogenomics (2003) 0.84
Psychological stress is associated with relapse in type 1 autoimmune hepatitis. Liver Int (2010) 0.83
Unimpaired osmotic water permeability and fluid secretion in bile duct epithelia of AQP1 null mice. Am J Physiol Gastrointest Liver Physiol (2002) 0.83
Hepatic uptake and biliary excretion of manganese in the little skate, Leucoraja erinacea. Comp Biochem Physiol C Toxicol Pharmacol (2008) 0.82
Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression. Am J Physiol Gastrointest Liver Physiol (2007) 0.81
Membrane trafficking of the human organic anion-transporting polypeptide C (hOATPC). Pharm Res (2007) 0.81
Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology (2013) 0.81
A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis. Hepatology (2012) 0.81
Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct-ligated rats. Drug Metab Dispos (2006) 0.80
All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice. J Pharmacol Exp Ther (2014) 0.79
The Role of Inflammation in the Mechanisms of Bile Acid-Induced Liver Damage. Dig Dis (2017) 0.78
Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity. Am J Physiol Gastrointest Liver Physiol (2013) 0.78
Retention of structural and functional polarity in cultured skate hepatocytes undergoing in vitro morphogenesis. Comp Biochem Physiol B Biochem Mol Biol (2006) 0.78
Cholestatic syndromes. Curr Opin Gastroenterol (2003) 0.76
A biliary milestone: functional expression of the human bile salt export pump. Gastroenterology (2002) 0.75
Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. J Clin Gastroenterol (2016) 0.75
A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. World J Gastroenterol (2006) 0.75
A cholecystohepatic shunt pathway: does the gallbladder protect the liver? Gastroenterology (2012) 0.75
Small-duct sclerosing cholangitis associated with Schistosoma mansoni. Hepatology (2010) 0.75
Cholestatic syndromes. Curr Opin Gastroenterol (2002) 0.75
Phloracetophenone-induced choleresis in rats is mediated through Mrp2. Am J Physiol Gastrointest Liver Physiol (2007) 0.75
Sperber I. Secretion of organic anions in the formation of urine and bile[Pharmacol. Rev. 1959;11:109-134]. J Hepatol (2002) 0.75
Differential effects of hydroxyacetophenone analogues on the transcytotic vesicular pathway in rat liver. Eur J Pharmacol (2006) 0.75